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Summary 
Background 
Treatment of actinic keratoses (AK) is a potentially effective strategy for prevention of 
cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential 
benefits of AK treatment in terms of skin cancer reduction has received little attention to date.   
Objectives 
(1) To investigate patient preferences for AK topical treatments using a discrete choice 
experiment (DCE); (2) To evaluate patient willingness to trade between clinical benefit and 
medical burden. 
Methods 
The DCE was conducted as part of a study to establish the feasibility of a phase III RCT 
evaluating prevention of cSCC using currently available topical interventions.  Preferences 
were elicited by asking patients to make a series of choices between treatment alternatives with 
different hypothetical combinations of attribute levels. Willingness to trade between treatment 
attributes was estimated using a flexible choice model that allows for the heterogeneity of 
patient preferences.  
Results 
109 patients with AK completed the DCE.  The majority of patients who expressed valid 
preferences were willing to accept some reduction in both prophylactic and cosmetic efficacy 
to reduce the burden of the treatment regimen, the severity of skin reaction and other adverse 
effects.  Patients may reject treatment if the perceived therapeutic benefit is outweighed by the 
subjective burden of treatment. 
Conclusions 
Evidence of significant variation in the perceived utility of treatments across patients highlights 
the importance of taking individual patient preferences into account to improve AK treatment 
acceptability and adherence. 
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What’s already known about this topic? 
• There are multiple therapies of varying efficacy licensed for the treatment of actinic 
keratoses (AK), but none yet proven to reduce skin cancer incidence. 
• AK treatments all carry a therapeutic burden including pain, local skin inflammation 
and inconvenience of regimen. 
• Discrete choice experiments (DCE) are increasingly used to elicit patient preferences 
and thereby improve adherence to treatment. 
What does this study add? 
• This is the first study to investigate patient willingness to undergo AK treatment using 
a discrete choice experiment. 
• The majority of patients are able to discriminate between treatment characteristics and 
many of these patients are willing to make trade-offs between attributes. 
• Patients are prepared to accept some reduction in efficacy in order to reduce treatment 
burden.  
What are the clinical implications of the work? 
• Treatment of AK is a potential strategy for skin cancer prevention, but is only feasible 
if patients are willing to consent and adhere to therapy. 
• Knowledge of patient preferences will help to optimise the design of treatment 
protocols given that no currently available AK treatment is clearly superior in terms of 
both greater clinical benefit and reduced medical burden. 
 
Introduction 
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer in the 
UK, accounting for approximately 23% of the 132,000 new cases of non-melanoma skin cancer 
registered in 2014.1,2 Cutaneous SCC incidence has more than doubled in the past 10 years and 
rates are predicted to continue rising with the increasing population of elderly individuals, 
placing a significant burden on health-care resources.3 Ultraviolet radiation (UVR) is the 
principle environmental carcinogen and an estimated 23% of the UK population over 60 years 
have significant sun-damage and pre-cancerous skin lesions in the form of actinic keratoses 
(AK).4  AK are considered to be precursor lesions for cSCC with a number of studies 
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demonstrating a close relationship between AK numbers and cSCC risk,5,6,7 with 65% of cSCC 
arising from previously identified AK.8 Treatment of AK might therefore provide an effective 
strategy for cSCC prevention, although this hypothesis has yet to be subjected to rigorous 
testing.9,10 
AK can be individually treated with lesion-directed therapies such as surgery or 
cryotherapy, or a whole area of skin bearing multiple AK can be treated with field-directed 
therapy, which also aims to clear sub-clinical AK.  A number of topical AK treatments with 
differing mechanisms of action are currently licensed in the UK for self-administration (e.g. 
diclofenac gel; 5-fluorouracil (5-FU) cream; imiquimod cream; ingenol mebutate gel). They 
vary in terms of therapeutic burden to patients (e.g. frequency of application, duration of 
treatment course, severity of local skin reactions and adverse effects), as well as their efficacy 
(i.e. proportion of AK cleared and persistence of clearance).  For example, topical diclofenac 
3% gel tends to cause fewer local skin reactions than 5-fluorouracil with salicylic acid, but 
treatment duration is longer and it is less effective in clearing AK.9 Such factors may impact 
upon patient treatment preferences; understanding such preferences is important for improving 
acceptability of, and adherence to, these topical AK treatments.11  
This study investigated patient preferences for topical AK treatments by means of a 
discrete choice experiment (DCE). DCEs are increasingly used in healthcare research to elicit 
patient preferences.12 They are based upon the premise that medical treatments are 
characterised by a set of attributes and that the attractiveness of a specific treatment is a function 
of the levels of these attributes.13 The relative importance of attributes is assessed by offering 
patients a series of choices between treatment alternatives that have different hypothetical 
combinations of attribute levels. This methodology has not previously been applied to 
understanding patient preferences in AK treatment.  
 
Methods 
Study design 
Patients were presented with a series of choices between two hypothetical topical treatments 
for AK (A and B) and a ‘no treatment’ opt-out option in each choice set.  The hypothetical 
nature of the treatments provided an opportunity to examine preferences across a wider range 
of attribute level combinations than exists in currently available treatments.  Moreover, the true 
attribute levels of existing treatments do not need to be known to elicit patients’ willingness to 
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trade between attributes. This willingness to trade was estimated using a flexible choice model 
that allows for the heterogeneity of respondents’ preferences.  
The selection of treatment attributes and levels is fundamental to obtaining valid DCE 
results.13 In this study, an initial selection was made by one of the authors (CP) based upon 
review of the literature and expert knowledge from clinical practice.  This initial selection was 
used in a pilot DCE administered to seven AK patients who subsequently participated in a 
focus group exploring their perspectives on the preliminary DCE design. The findings from 
this exercise were used to modify the initial choice of both attributes and associated levels, 
with Table 1 providing details of the final DCE design. Of the five attributes, three were 
associated with the burden of medication, (intensity and length of treatment, severity of local 
skin reaction, and occurrence of flu-like systemic side effects) and two with the efficacy of 
treatment (improvement in skin appearance and reduction in skin cancer risk). Attribute levels 
were chosen to be comparable, although not identical, with those of currently prescribed creams 
to ensure the clinical relevance of the results, with three levels specified for the reduction in 
skin cancer risk and two levels for the four other attributes.   
Experimental design techniques14, 15 were used to construct an orthogonal main effects 
plan consisting of 12 of the 48 possible combinations of treatment attributes and levels. To 
validate patient responses, a further two choice sets were added to the DCE: the first checked 
for rationality of patient choices by including a treatment with unambiguously higher levels of 
medical burden and lower levels of clinical efficacy; the second checked for consistency by 
including a treatment which was identical to one of the main choice sets, but with treatments 
A and B switched. The sequencing of the 14 choice sets was randomly generated for each 
individual patient questionnaire to mitigate against bias caused by learning or fatigue.16 
 
Study sample and elicitation mode 
The DCE was conducted as part of Skin cancer Prevention in Organ Transplant patients 
(SPOT), a multi-centre, randomised, 3-arm open-label phase II feasibility study comparing 
topical treatment of AK as a strategy for prevention of invasive cSCC.17 Patients were recruited 
between December 2014 and June 2016, with organ transplant recipients (OTRs) recruited at 
Manchester Royal Infirmary, Royal Free Hospital London and Barts Health NHS Trust 
London, and immunocompetent patients (ICPs) at Churchill Hospital Oxford and Ninewells 
Hospital Dundee. Inclusion criteria were age 18 years and above; at least 10 AK occurring 
within the same or on adjacent body sites in immunosuppressed OTRs; and a past or current 
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history of AK in ICPs. The sample size N was determined by a power calculation for the main 
SPOT study, not the DCE, but the following rule of thumb18, 19 was used to check that this 
would be adequate to detect the main effects in the choice model analysis: 
( ) ( ) ( ) ( )500 500 3 12 3 41.7N c t a> × × = × × =  (1) 
where c=3 is the largest number of levels specified for any of the attributes (20%, 50% and 
60% skin cancer risk reductions), t=12 the number of choice sets or tasks utilised in the choice 
model analysis and a=3 the number of alternatives in each task (A, B or no treatment). 
The DCE formed part of a written questionnaire completed in clinic by patients before 
starting their randomised intervention (see Supplementary materials). Information collected 
included demographic data, history of skin problems including AK and previous treatments for 
AK. A detailed explanation of the DCE was provided to patients, with a trial clinician in 
attendance to answer queries.  Patients were asked to report on their experience of completing 
the DCE.  
 
Statistical analysis 
Preference parameters were estimated based on a random utility model in which the utility or 
value that patient i assigns to treatment j in choice set s, , is assumed to be the sum of a 
systematic component based on the attributes included in the DCE, and an error term : 
  (2) 
where the treatment constant  reflects the relative value of a treatment with maximum 
burden and minimum efficacy to no treatment at all, the utility weights  (k=1,…K) indicate 
the importance of the attributes  relative to one another, and the absence of interaction terms 
between attributes is dictated by the DCE design.  The preferred generalised multinomial logit 
(G-MNL) specification20 takes preference heterogeneity into account by allowing both the 
treatment constant and the scale of the error term to vary randomly across patients.  The model 
was estimated in Stata 1421 by maximum simulated likelihood using 2000 Halton draws.  
Estimated utility weights were used to calculate patients’ willingness to trade between 
treatment attributes on the assumption that the weights for both reductions in skin cancer risk 
and improvements in skin appearance are linear over the range of levels specified in the DCE.  
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Funding and ethics 
SPOT is funded by the Research for Patient Benefit programme of the National Institute for 
Health Research. The study is approved by the Research Ethics Committees of the participating 
sites (EudraCT number 2013-000893-32) and all patients provided written informed consent. 
 
Results 
Sample characteristics 
109 of 111 patients recruited into the SPOT study completed the DCE, of which 48 were OTRs 
and 61 were ICPs. Patient characteristics are summarised in Table 2. Patients were 
predominantly male with mean age 68 years (range 46 to 91 years). Most patients considered 
their AK to be moderately serious in nature, with over 70% selecting one of the three middle 
categories equating to moderately serious on a 7-point Likert scale. More than 80% of 
participants had received prior treatments for AK with more than half reporting previous use 
of a topical treatment, including 5-fluorouracil cream (48%), imiquimod cream (17%) and 
diclofenac gel (12%). As detailed in Table 2, there are a few significant differences between 
the OTR and ICP sub-populations, which include younger age of OTR and acral site of AK.  
 
Patient preferences for treatment attributes 
Figure 1 details the selection of the choice model sample by patient type. 25 respondents failed 
either one or both of the validity tests and were excluded from the subsequent DCE analysis. 
Patients were asked how difficult they found the DCE on a 5 point Likert scale (see 
supplementary Table 1), with a Mann-Whitney U test revealing that these patients found the 
DCE significantly more difficult to complete than those providing valid responses (p<0.05).  A 
further 26 patients were classified as ‘non-traders’: they chose the option with the better level 
of one specific attribute (most commonly the hypothetical treatment with the higher level of 
cancer risk reduction – see supplementary Table 2) in all choice sets, revealing no willingness 
to trade between attributes at the levels specified in the study. The choices of these 26 patients 
are consistent with so-called ‘lexicographic preferences’ but not with the DCE methodology 
and they were therefore also excluded. The final choice model sample therefore comprised the 
58 respondents with valid responses whose best option choices revealed that they were willing 
to trade between attributes.  In the majority of cases (n=55) these respondents provided 
responses for all choice sets.  
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The choice model estimates are presented in Table 3. The signs of the estimated utility 
weights on all treatment attributes are consistent with a priori expectations, since positive 
values imply preferences for a lower medical burden and higher clinical efficacy. It follows 
that setting all attribute levels to zero will result in the worst possible hypothetical treatment 
option, one which has to be applied twice daily for 12 weeks, causes severe inflammation and 
systemic symptoms and results in only a moderate improvement in skin appearance and a 20% 
fall in the chance of developing skin cancer.  The treatment constant provides a prediction of 
the mean expected utility value of this treatment option, with the positive value providing 
strong evidence (p<0.01) that it would be preferable to no treatment at all for the typical patient. 
Nevertheless, the estimate of the standard deviation of the treatment constant indicates 
significant preference heterogeneity, such that the expected utility value of the worst possible 
option will be negative – i.e. worse than no treatment at all – for about 0.3% of patients.  The 
‘no treatment’ option was chosen as the best option in six choice sets by one patient in the 
choice model sample.  A Wald test failed to reject the linearity of utility weights over the range 
of skin cancer risk reductions included in the DCE (p>0.10), with the value of a change from 
a 20% to a 60% fall being insignificantly different from one third more than that of a change 
from a 20% to a 50% fall, holding all other attributes constant.   
 
Trade-offs 
Table 4 shows patients’ willingness to trade between treatment attributes based on the 
estimated utility weights.1  With respect to medical burden, patients place the highest value on 
a reduction in severity of the local skin reaction (from severe to mild), followed by the length 
and intensity of the treatment regimen (from twice daily for 12 weeks to daily for a week) and 
finally the elimination of flu-like systemic symptoms. Patients are willing to accept increases 
in the risk of developing skin cancer of 13.4, 9.7 and 6.7 percentage points respectively – or 
forgo improvements in skin appearance of 37.0, 26.9 and 18.5 percentage points – in order to 
mitigate these three aspects of treatment burden.  Patients value changes in skin cancer risk 
more highly than in cosmetic outcome, being prepared to accept a 0.36 percentage point 
increase in the risk of developing skin cancer to obtain a 1 percentage point improvement in 
skin appearance.  
                                                          
1 Given the linearity assumption, the implied utility weights for a 1% reduction in skin cancer risk and 1% 
improvement in skin appearance are respectively 0.056 = (1.756/30+2.142/40)/2 and 0.020 = 1.016/50. 
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Discussion 
Keratinocyte skin cancers are increasingly common creating both health burden and expense 
in our ageing population. They are especially burdensome in immunosuppressed patients, such 
as OTRs, who have an approximately 100-fold increased risk of developing cSCC and 
accelerated progression from AK to cSCC.22 Prevention of cSCC through systematic targeting 
of the common and visible precursor, AK, sounds logical, but is only feasible if effective 
treatments are acceptable to the patient population needing to use them. Previous studies of 
topical AK treatments have included patient reported outcomes as secondary outcomes, 
including patients’ tolerance of the regimen, satisfaction with the cosmetic appearance and 
choice of future treatment.  This is the first study, however, to systematically explore patient 
preferences for AK treatments using a DCE designed to investigate their willingness to undergo 
treatment and, if so, to trade between different treatment attributes.  Understanding these 
preferences will help health professionals and decision-makers to optimise the design of 
treatment protocols for AK. This is a live issue since there is no currently available treatment 
that is clearly superior with respect to acceptability, efficacy and subsequent reduction in skin 
cancer risk. For example, Stockfleth et al.9 find that 5-fluorouracil cream is more clinically 
effective than diclofenac gel, but it is less well tolerated with a higher proportion of patients 
reporting local adverse reactions. In this DCE study we have shown that the majority of patients 
are able to discriminate between treatment attributes showing specific preferences that can be 
incorporated into future strategies to improve adherence.   
Our results are consistent with a priori expectations in that patients overwhelmingly 
express preferences for lower treatment burden and higher clinical efficacy.  Our results also 
show that nearly 70% of patients who expressed valid preferences revealed a willingness to 
make trade-offs between attributes in their treatment option choices. The remainder based their 
best option choices on the better level of one specific attribute only and for roughly half of 
these patients, in both the OTR and ICP sub-samples, this single factor was a greater reduction 
in skin cancer risk.  The apparent strength of preferences among this sub-set of non-traders, 
even if they are the result of heuristic decision-making,23 may be taken as an indication that 
they would be almost certain to accept treatment irrespective of the severity of the treatment 
burden.  
The choice model estimates imply that patients who are willing to trade between 
attributes would accept some reduction in both the prophylactic and cosmetic benefit of 
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treatment in order to reduce the length and intensity of treatment regimens, pain and skin 
inflammation due to local adverse reactions, and the incidence of other side effects. Patients’ 
preferences may be influenced by length of treatment course, as in preference for 
photodynamic therapy,10 and/or by local (and systemic) adverse events with skin inflammation 
being a frequent complication of topical treatments for AK.24 In this DCE study, the 
hypothetical attribute levels were chosen so as to provide health professionals with relevant 
information to make clinical decisions that reflect patient preferences between currently 
licenced topical treatments. 
The choice model estimates also demonstrate significant variation in the value that 
individual patients place on treatment options, although even the worst possible hypothetical 
treatment (high medical burden with low clinical efficacy) was preferable to no treatment for 
virtually all patients.  Nevertheless, a very small proportion of patients might be expected to 
reject such an option, with one participant choosing no treatment as the best option in a number 
of the choice sets presented in the DCE. Serra-Guillen et al.25 report that only 70% of patients 
treated with imiquimod would be willing to repeat the treatment. Moreover, patients who are 
prepared to accept treatment but do not value it highly might be less likely to adhere to the 
regimen. The clinical importance of non-adherence has been highlighted in the most recent 
Cochrane review on AK treatment.24  
Our study has several potential limitations. First, although the design of the DCE was 
based on expert opinion and further refined by results of a pilot exercise, it is possible that we 
did not include all attributes that are relevant to patient preferences for AK treatment. Second, 
respondents may have been unfamiliar with different AK treatments or did not fully understand 
the nature of the choices that they were being asked to make.  However, most respondents had 
previously received AK treatments – and over half had experienced a topical treatment – with 
hypothetical attribute levels chosen to be comparable with those of the currently prescribed 
agents.  Moreover, the DCE was completed in clinic with a research nurse in attendance to 
check on the respondent’s understanding. Third, the DCE design allowed only for main effects 
and we were therefore unable to identify any specific effects associated with particular 
combinations of attribute levels.  Previous research has found that main effects typically 
account for the bulk of the variation in a DCE with interactions playing a smaller role.26 Fourth, 
the sample size was determined by a power calculation for the main SPOT study, not the DCE, 
but an established rule of thumb18, 19 indicated that the choice model sample was more than 
adequate to detect the main effects.  Fifth, the results may be sensitive to the choice model 
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specification.  However, a robustness analysis produced virtually identical findings across a 
range of alternative logit model specifications (see supplementary Table 3).  Finally, our 
findings are based on a sample of patients recruited from specialist clinics in a single country 
(UK) and may not necessarily be generalisable to treatment of AK in other settings. Preferences 
for attributes/levels may differ according to a number of factors including age, sex, education, 
patient type and prior medical history including previous AK treatments, but we were not able 
to reliably demonstrate evidence of significant differences in treatment valuations between 
patients with different observable characteristics given the limited sample size. Overall, 
however, we believe the clinical setting and patient characteristics are representative of current 
AK treatment practice in secondary care in the United Kingdom. 
 
Conclusion 
This study demonstrated that patients may reject an AK treatment if the perceived value of the 
therapeutic benefits is outweighed by the subjective costs associated with the medical burden.  
Moreover, most patients would be prepared to accept some reduction in both the prophylactic 
and therapeutic efficacy of treatment in order to reduce the length and intensity of the regimen, 
and local or systemic symptoms including skin inflammation and pain.  This will impact the 
feasibility of skin cancer prevention strategies that include AK treatments.  Evidence of 
significant variation in the perceived utility of treatments between patients highlights the 
importance of taking individual patient preferences into consideration as part of clinical 
decision-making in order to improve adherence to topical AK treatments. 
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Figure 1. DCE Study Flow Diagram 
 
 
 
 
  
 
 
  
Assessed for eligibility (n=111) 
Organ transplant recipients (OTR) n=50  
Immunocompetent (ICP) n=61 
 
OTR Excluded (n= 2) 
♦   Not meeting inclusion criteria (n=1) 
♦   Declined to complete initial 
questionnaire (n=1) 
ICP – choice model sample  (n= 33) 
ICP – Valid DCE response sample (n= 48) 
Non-traders excluded (n=15) 
ICP - DCE study population (n= 61) 
♦ No DCE responses (n= 2) 
♦ Failed consistency test (n= 7) 
♦ Failed rationality test (n= 2) 
♦ Failed both tests (n= 2) 
OTR - Valid DCE response sample (n=36) 
Non-traders excluded (n=11) 
OTR - DCE study population (n= 48) 
♦ Failed consistency test (n= 5) 
♦ Failed rationality test (n= 3) 
♦ Failed both tests (n= 4) 
 
OTR - choice model sample (n=25) 
Allocation 
Choice model 
sample n=58 
Valid Preferences 
Expressed n=84 
Entered SPOT study 
(n=109) 
Enrollment 
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Table 1. Attributes and levels for hypothetical AK treatments 
Attribute Level 
Intensity and length of treatment 1 
0 
Daily for 1 week 
Twice daily for 12 weeks 
Severity of reaction 1 
0 
Mild inflammation with some discomfort  
Severe inflammation with moderate pain  
Other side effects 1 
0 
No other side effects  
Flu-like symptoms, such as fever, fatigue, 
headache, nausea, diarrhoea and muscle pain 
Improvement in skin appearance 0 
 
1 
Moderate improvement with 50% clearance of AK 
skin lesions  
Big improvement with 100% clearance of AK skin 
lesions  
Reduction in risk of skin cancer 0 
1 
2 
20% 
50% 
60% 
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Table 2:  Patient characteristics  
 
Patient Characteristic 
DCE study 
population (n=109) 
OTR - DCE study 
population (n=48) 
ICP - DCE study 
population (n=61) 
Age 69.63   [45.83-90.89] 65.72* [45.83-82.44] 72.69* [50.45-90.89] 
Male 78.90% (86) 81.25% (39) 77.05% (47) 
Organ transplant recipient 44.04% (48) 100.0% (48)   0.00% (0) 
Age first left education 
  
16 years or less 46.79% (51) 41.67% (20) 50.82% (31) 
17-19 years old 23.85% (26) 29.17% (14) 19.67% (12) 
20 years or over 28.44% (31) 27.08% (13) 29.51% (18) 
Not supplied   0.92% (1)   2.08% (1)   0.00% (0) 
Time since most recent diagnosis 
 
Less than 1 day   1.83% (2)   0.00% (0)   3.28% (2) 
Less than 3 months   1.83% (2)   2.08% (1)   1.64% (1) 
Between 3 months and 1 year   8.26% (9)   8.33% (4)   8.20% (5) 
Between 1 and 3 years 14.68% (16) 10.42% (5) 18.03% (11) 
Between 3 and 10 years 34.86% (38) 35.42% (17) 34.43% (21) 
More than 10 years 37.61% (41) 41.67% (20) 34.43% (21) 
Not supplied   0.92% (1)   2.08% (1)    0.00% (0) 
Areas affected by AK 
  
Number of areas affected   4.23     [1-12]   4.65     [1-12]   3.90     [1-11] 
Face 63.30% (69) 70.83% (34) 57.38% (35) 
Nose 38.53% (42) 35.42% (17) 40.98% (25) 
Forehead 46.79% (51) 45.83% (22) 47.54% (29) 
Scalp 51.38% (56) 56.25% (27) 47.54% (29) 
Ears 34.86% (38) 37.50% (18) 32.79% (20) 
Hands 48.62% (53) 64.58%* (31) 36.07%* (22) 
Arms 38.53% (42) 50.00%* (24) 29.51%* (18) 
Legs 27.52% (30) 29.17% (14) 26.23% (16) 
Feet   6.42% (7) 10.42% (5)   3.28% (2) 
Neck 22.94% (25) 20.83% (10) 24.59% (15) 
Chest 22.02% (24) 20.83% (10) 22.95% (14) 
Back 20.18% (22) 20.83% (10) 19.67% (12) 
Other   1.83% (2)   2.08% (1)   1.64% (1) 
Self-rated seriousness of AK condition 
1. Not serious   7.41% (8)   2.13% (1) 11.48% (7) 
2 16.67% (18)   8.51%*  (4) 22.95%* (14) 
3 25.00% (27) 36.17%*  (17) 16.39%* (10) 
4. Moderately serious 25.00% (27) 25.53% (12) 24.59% (15) 
5 17.59% (19) 17.02% (8) 18.03% (11) 
6   4.63% (5)   6.38% (3)   3.28% (2) 
7. Very serious   3.70% (4)   4.26% (2)   3.28% (2)     
Received previous treatment for AK  83.49% (91) 83.33% (40) 83.61% (51) 
Past cryotherapy 57.80% (63) 64.58% (31) 52.46% (32) 
Past photodynamic therapy 10.09% (11) 10.42% (5)   9.84% (6) 
Past Diclofenac (Solaraze®) gel 11.93% (13) 10.42% (5) 13.11% (8) 
Past skin surgery 42.20% (46) 41.67% (20) 42.62% (26) 
Past 5-fluorouracil (Efudix®) cream 47.71% (52) 43.75% (21) 50.82% (31) 
Past imiquimod (Aldara®) cream 16.51% (18) 20.83% (10) 13.11% (8) 
Past other treatment   9.17% (10) 10.42% (5)   8.20% (5) 
Does not remember past treatment   4.59% (5)   6.25% (3)   3.28% (2)     
DCE difficulty (5=highest)   2.73       [1-5]   2.79       [1-4]   2.68       [1-5] 
Notes: Continuous variables show mean and range [in square brackets]. 
Dummy variables show percentage and number (in brackets). 
* Indicates a statistically significant difference between the OTR and ICP samples at the 5% level. 
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Table 3: Generalised multinomial logit (G-MNL) model estimation results 
 
 
Coefficient estimate 
[95% Confidence interval] 
Attributes  
Regimen: (reference level twice daily for 12 weeks)  
 Daily for 1 week 
 
0.546*** 
[0.217,0.875] 
Local skin reaction: (reference level severe)  
 Mild 0.751*** 
[0.359,1.142] 
Systemic effects: (reference level flu-like symptoms)  
 No other side effects  0.376** 
[0.059,0.692] 
Skin appearance: (reference level moderate improvement)  
 Big improvement 1.016*** 
[0.582,1.450] 
Cancer risk: (reference level 20% fall)  
 50% fall 1.756*** 
[0.786,2.725] 
 60% fall 2.142*** 
[0.933,3.352] 
Treatment constant  
Mean 11.590*** 
[4.778,18.400] 
Standard deviation 4.229*** 
[2.221,6.236] 
  
Scale heterogeneity parameter 0.657** 
[0.128,1.185] 
Number of observations 2076 (58 respondents × 12 choices, minus 12 missing values). 
Log-likelihood = -346.1.   
Akaike information criterion = 710.2. Bayesian information criterion 761.0.  
* p < 0.10, ** p < 0.05, *** p < 0.01. 
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Table 4: Estimates of Willingness to Trade Treatment Burden for Clinical efficacy 
 
 
Attributes 
Worse cosmetic 
outcome 
Percentage points 
Higher skin  
cancer risk 
Percentage points 
Regimen: (reference level twice daily for 12 week)   
 Daily for 1 week 
 
26.9** 
[11.2– 42.5] 
9.7** 
[3.1–16.4] 
Local skin reaction: (reference level severe)   
 Mild 37.0** 
[19.6– 54.3] 
13.4** 
[5.3–21.5] 
Systemic effects: (reference level flu-like symptoms)   
 No other side effects  18.5* 
[1.4– 35.6] 
6.7* 
[1.7–11.7] 
Skin appearance   
 1 percentage point improvement  0.36** 
[0.23– 0.50] 
Estimates presented as mean [95% confidence interval]. A positive willingness to pay means that patients are 
willing to trade a reduction in medical efficacy for the specified level or improvement in the attribute.  * p < 
0.05, ** p < 0.01 
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Supplementary material:  Introduction to DCE  
  
20 
21 
 
  
22 
 
  
23 
 
  
24 
Supplementary Table 1: Difficulty with DCE completion by subgroup 
 Very 
easy 
Rather 
easy 
Neither 
easy nor 
difficult 
Rather 
difficult 
Very 
difficult 
Total 
Invalid DCE response subgroup 3 2 9 9 1 24 
Non-trader subgroup 4 11 8 2 1 26 
Final DCE analysis subgroup 6 18 23 9 2 58 
DCE study population 13 31 40 20 4 108 
Notes:  One participant in the invalid DCE response subgroup did not answer the question. 
 
 
 
Supplementary Table 2: ‘Non-trader’ Choices by Patient Type and Dominant Attribute 
 Proportion of ‘non-traders’ in valid sample 
(absolute number in brackets) 
 
Dominant attribute OTR patients ICP patients 2-way t test p value 
Intensity and length of 
treatment 
0.0%   (0) 8.3%   (4) 0.078* 
Severity of reaction 5.6%   (2) 2.1%   (1) 0.402 
Other side effects 5.6%   (2) 2.1%   (1) 0.402 
Improvement in skin 
appearance 
5.6%   (2) 4.2%   (2) 0.771 
Reduction in risk of 
skin cancer 
13.9% (5) 14.6% (7) 0.929 
Total 30.1% (11) 31.3% (15) 0.947 
Notes:   * p < 0.10.  ‘Non-traders’ chose the option with the better level of one specific attribute in all choice 
sets, ignoring all other differences between the alternatives. 
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Supplementary Table 3: Alternative choice model estimation results  
The Table below presents the choice model estimates for each of the logit specifications considered in 
the study.  Column 1 reports the results for a basic multinomial logit (MNL) model specification.  The 
mixed logit (MIXL) specification in column 2 allows the treatment constant, and thereby the mean value 
of treatments, to vary randomly across all participants.  The scaled multinomial logit (S-MNL) 
specification in column 3 captures preference heterogeneity for individual treatment attributes by 
allowing the standard deviation of the idiosyncratic error term to vary randomly across participants.  Our 
preferred generalised multinomial logit (G-MNL) model specification in column 4 allows for both 
sources of random preference heterogeneity.  The reported log likelihood and information criteria 
indicate that all three variants are superior to the basic MNL specification, with the G-MNL model 
chosen on this basis and the statistical significance of both random preference heterogeneity parameters.  
Attempts to allow for heterogeneous preferences due to observable patient characteristics failed due to 
the sparseness of the data,1 with the ‘no treatment’ option only chosen by one patient in six choice sets.  
Finally, the rank-ordered logit (ROL) specification in column 5 is based on that of the MNL model, but 
estimation of the utility weights makes use of the sample information on both best and worst option 
choices.  A Hausman test failed to reject the null hypothesis that the same utility weights were applied 
in making both choices (p>0.10).  
 
Supplementary references 
1. Hosmeer DW, Lemeshow S and Sturdivant RX.  Applied Logistic regression, 3rd Edition.  New 
Jersey: Wiley, 2013. 
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 1 2 3 4 5 
 MNL MIXL S-MNL G-MNL ROL 
Attribute      
Regimen: (reference level twice daily for 12 weeks)      
 Daily for 1 week 0.466*** 
[0.258,0.674] 
0.468*** 
[0.260,0.677] 
0.577*** 
[0.215,0.939] 
0.546*** 
[0.217,0.875] 
0.452*** 
[0.247,0.658] 
Skin reaction: (reference level severe)      
 Mild 0.642*** 
[0.429,0.855] 
0.645*** 
[0.431,0.860] 
0.794*** 
[0.346,1.243] 
0.751*** 
[0.359,1.142] 
0.606*** 
[0.396,0.816] 
Other side effects: (reference level flu-like symptoms)      
 No other side effects 0.337*** 
[0.133,0.541] 
0.338*** 
[0.133,0.543] 
0.376** 
[0.036,0.715] 
0.376** 
[0.059,0.692] 
0.337*** 
[0.147,0.527] 
Appearance: (reference level moderate improvement)      
 Big improvement 0.844*** 
[0.638,1.050] 
0.847*** 
[0.640,1.054] 
1.053*** 
[0.629,1.476] 
1.016*** 
[0.582,1.450] 
0.783*** 
[0.577,0.988] 
Cancer risk: (reference level 20% fall)      
 50% fall 1.330*** 
[0.980,1.681] 
1.334*** 
[0.981,1.686] 
1.817*** 
[0.947,2.688] 
1.756*** 
[0.786,2.725] 
1.297*** 
[0.982,1.612] 
 60% fall 1.595*** 
[1.198,1.993] 
1.602*** 
[1.203,2.000] 
2.230*** 
[1.147,3.314] 
2.142*** 
[0.933,3.352] 
1.523*** 
[1.134,1.912] 
Treatment constant      
Mean 2.053** 
[0.068,4.039] 
19.380* 
[-1.892,40.649] 
2.241** 
[0.216,4.265] 
11.590*** 
[4.778,18.400] 
2.911*** 
[1.644,4.177] 
Standard deviation  ~ 
 
8.930** 
[1.078,16.781] 
~ 
 
4.229*** 
[2.221,6.236] 
~ 
 
Scale heterogeneity parameter ~ 
 
~ 
 
0.733*** 
[0.323,1.142] 
0.657** 
[0.128,1.185] 
~ 
 
Observations 2076 2076 2076 2076 2076 
Individuals 58 58 58 58 58 
Log-likelihood -367.2 -347.5 -361.0 -346.1 -429.1 
Akaike Information Criteria  748.4 711.1 737.9 710.2 872.3 
Bayesian Information Criteria 787.9 756.2 783.0 761.0 911.7 
Hausman test (p value) ~ ~ ~ ~ 0.254 
95% confidence interval in parentheses.  * p < 0.10, ** p < 0.05, *** p < 0.01 
